E-LIB Suche - Ergebnisse für: Himmelsbach, Vera

1

Disease Etiology Impact on Outcomes of Hepatocellular Carci..:

Rossari, Federico ; Tada, Toshifumi ; Suda, Goki...
Liver Cancer. , 2024

Link: https://doi.org/10.1159/..

2

Safety and Efficacy of Lenvatinib in Very Old Patients with..:

Camera, Silvia ; Rimini, Margherita ; Rossari, Federico...
Targeted Oncology. 19 (2024) 1 - p. 29-39 , 2024

Link: https://doi.org/10.1007/..

3

Impact of body mass index on the prognosis of unresectable ..:

Rimini, Margherita ; Stefanini, Bernardo ; Tada, Toshifumi...
Liver International. 44 (2024) 5 - p. 1108-1125 , 2024

Link: https://doi.org/10.1111/..

4

Systemic Drugs for Hepatocellular Carcinoma: What Do Recent..:

Himmelsbach, Vera ; Koch, Christine ; Trojan, Jörg.
Journal of Hepatocellular Carcinoma. 11 (2024) - p. 363-372 , 2024

Link: https://doi.org/10.2147/..

5

Adverse Events as Potential Predictive Factors of Activity ..:

Persano, Mara ; Rimini, Margherita ; Tada, Toshifumi...
Targeted Oncology. , 2024

Link: https://doi.org/10.1007/..

6

Sequential therapies after atezolizumab plus bevacizumab or..:

Persano, Mara ; Rimini, Margherita ; Tada, Toshifumi...
European Journal of Cancer. 189 (2023) - p. 112933 , 2023

Link: https://doi.org/10.1016/..

7

Real-World Data for Atezolizumab Plus Bevacizumab in Unrese..:

Rimini, Margherita ; Persano, Mara ; Tada, Toshifumi...
Targeted Oncology. 18 (2023) 2 - p. 221-233 , 2023

Link: https://doi.org/10.1007/..

8

Validation of the CRAFITY score in patients with hepatocell..:

Scheiner, Bernhard ; Sartoris, Riccardo ; D'Alessio, Antonio...
Journal of Hepatology. 78 (2023) - p. S491-S492 , 2023

Link: https://doi.org/10.1016/..

9

Efficacy and safety of immune checkpoint inhibitor rechalle..:

Scheiner, Bernhard ; Roessler, Daniel ; Phen, Samuel...
JHEP Reports. 5 (2023) 1 - p. 100620 , 2023

Link: https://doi.org/10.1016/..

10

α‐FAtE: A new predictive score of response to atezolizumab ..:

Rossari, Federico ; Tada, Toshifumi ; Suda, Goki...
International Journal of Cancer. 154 (2023) 6 - p. 1043-1056 , 2023

Link: https://doi.org/10.1002/..

11

Atezolizumab plus bevacizumab versus lenvatinib for unresec..:

Casadei-Gardini, Andrea ; Rimini, Margherita ; Tada, Toshifumi...
European Journal of Cancer. 180 (2023) - p. 9-20 , 2023

Link: https://doi.org/10.1016/..

12

Survival outcomes from atezolizumab plus bevacizumab versus..:

Rimini, Margherita ; Persano, Mara ; Tada, Toshifumi...
Journal of Cancer Research and Clinical Oncology. 149 (2023) 10 - p. 7565-7577 , 2023

Link: https://doi.org/10.1007/..

13

Impact of IDH1 mutation on clinical course of patients with..:

Kinzler, Maximilian N. ; Jeroch, Jan ; Klasen, Christina...
Journal of Cancer Research and Clinical Oncology. 149 (2023) 9 - p. 6391-6398 , 2023

Link: https://doi.org/10.1007/..

14

Efficacy and Safety of Atezolizumab and Bevacizumab in the ..:

Himmelsbach, Vera ; Pinter, Matthias ; Scheiner, Bernhard...
Cancers. 14 (2022) 7 - p. 1722 , 2022

Link: https://doi.org/10.3390/..

15

Atezolizumab Plus Bevacizumab in Patients with Advanced and..:

Sinner, Friedrich ; Pinter, Matthias ; Scheiner, Bernhard...
Cancers. 14 (2022) 23 - p. 5966 , 2022

Link: https://doi.org/10.3390/..